Dr. Ankur Bahl

Dr. Ankur Bahl is the Principal Director of Medical Oncology at Fortis Memorial Research Institute in Gurugram, bringing over 17 years of specialised clinical experience in cancer treatment. A graduate of Maulana Azad Medical College, Delhi, where he completed both his MBBS and MD in Medicine, Dr. Bahl furthered his expertise by obtaining his DM in Medical Oncology from the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi. He has also completed a specialized course on Adverse Drug Reactions, Drug Interactions, and Pharmacovigilance at the University of Oxford, UK, strengthening his evidence-based approach to cancer care.

Dr. Bahl's clinical depth encompasses the full spectrum of medical oncology, including chemotherapy for solid tumours, neoadjuvant and adjuvant chemotherapy protocols, immunotherapy using immune checkpoint inhibitors, targeted molecular therapies, and hormonal treatment for breast cancer. He is recognised as the lead author of the largest real-world Indian dataset on targeted therapy with Cetuximab in head and neck cancer, acute myeloid leukaemia treatment, and Human Papillomavirus epidemiology in the Indian population—publications that have shaped understanding of cancer patterns and treatment efficacy in the region. His commitment to evidence-based oncology is evident through his active participation in tumour boards, master classes, and workshops across India and internationally.

Dr. Bahl treats a substantial international patient cohort, welcoming patients from the Gulf Cooperation Council states, African nations, and South Asian countries seeking advanced oncological care. His fluency in English and Hindi enables seamless communication with diverse patient backgrounds. He provides comprehensive supportive and palliative care alongside curative treatments, ensuring patients receive holistic management throughout their cancer journey.

Fortis Memorial Research Institute, where Dr. Bahl practises, is a leading tertiary-care cancer centre in Gurugram with state-of-the-art infrastructure, dedicated oncology wards, advanced diagnostic and treatment facilities, and a strong international patient support team. The hospital maintains accreditation standards and offers integrated care with specialist nurses, nutritionists, and counsellors. International patients benefit from streamlined admission processes, translation services, and coordination of follow-up care. Dr. Bahl's position as Principal Director ensures that patients receive leadership-level oversight of their treatment strategy, with access to the latest clinical protocols and innovations in cancer therapy.